concizumab-mtci (Alhemo)
concizumab-mtci is an FDA-licensed reference biologic from Novo Nordisk Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
Alhemo concizumab-mtci
Novo Nordisk Inc.
- Approved
- Dec 20, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for concizumab-mtci, in chronological order.
Reference approval
Approval date of the reference concizumab-mtci product.
1 yr 6 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 5 yr 8 mo
Frequently asked questions
Are there biosimilars approved for concizumab-mtci (Alhemo)?
No 351(k) biosimilars or interchangeable biosimilars referencing concizumab-mtci are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.